Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -43.83% is 56% above its 5-year average of -99.05%, near the high end of its 5-year range (-3284.49%–51.85%).
94.31% above its 12-month average of -769.86%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -547.84%.
OPERATING MARGIN
-43.83%
OPERATING MARGIN AVG TTM
-769.86%
OPERATING MARGIN AVG 3Y
-270.13%
OPERATING MARGIN AVG 5Y
-99.05%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+94.31%
CURRENT VS 3Y AVG
+83.77%
CURRENT VS 5Y AVG
+55.75%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 747 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Monte Rosa Therapeutics, Inc.
Market Cap
$849.02M
Operating Margin
-43.83%
TTM Avg
-769.86%
3Y Avg
-270.13%
5Y Avg
-99.05%
Market Cap
$848.46M
Operating Margin
-1776.32%
TTM Avg
-888.16%
3Y Avg
-444.08%
5Y Avg
-444.08%
Market Cap
$845.57M
Operating Margin
-30.67%
TTM Avg
-52.06%
3Y Avg
-18.41%
5Y Avg
7.25%
Market Cap
$842.45M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$841.98M
Operating Margin
-69.75%
TTM Avg
-70.49%
3Y Avg
-9306.05%
5Y Avg
-9306.05%
Market Cap
$857.96M
Operating Margin
-174.65%
TTM Avg
-105.11%
3Y Avg
-66.40%
5Y Avg
-66.40%
Market Cap
$834.74M
Operating Margin
-348.46%
TTM Avg
-328.22%
3Y Avg
-265.67%
5Y Avg
-226.03%
Market Cap
$865.70M
Operating Margin
-8.31%
TTM Avg
-16.09%
3Y Avg
-30.50%
5Y Avg
-38.64%
Market Cap
$872.19M
Operating Margin
42.63%
TTM Avg
28.06%
3Y Avg
-1.90%
5Y Avg
-7.11%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | $849.02M | -43.83% | -769.86% | -270.13% | -99.05% |
| Alumis Inc. (ALMS)vs › | $848.46M | -1776.32% | -888.16% | -444.08% | -444.08% |
| QuidelOrtho Corporation (QDEL)vs › | $845.57M | -30.67% | -52.06% | -18.41% | 7.25% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $842.45M | 0.00% | 0.00% | 0.00% | 0.00% |
| Beta Bionics, Inc. (BBNX)vs › | $841.98M | -69.75% | -70.49% | -9306.05% | -9306.05% |
| SL Science Holding Ltd (SLBT)vs › | $857.96M | -174.65% | -105.11% | -66.40% | -66.40% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $834.74M | -348.46% | -328.22% | -265.67% | -226.03% |
| SI-BONE, Inc. (SIBN)vs › | $865.70M | -8.31% | -16.09% | -30.50% | -38.64% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $872.19M | 42.63% | 28.06% | -1.90% | -7.11% |
| Jade Biosciences, Inc. (JBIO)vs › | $819.78M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
92.9%
Operating Margin
-43.8%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -547.84% |
| 2026-03-31 | -1188.46% |
| 2025-12-31 | -1787.67% |
| 2025-09-30 | -258.26% |
| 2025-06-30 | -67.06% |
| 2025-03-31 | 51.85% |
| 2024-12-31 | 21.44% |
| 2024-09-30 | -287.84% |
| 2024-06-30 | -695.25% |
| 2024-03-31 | -3284.49% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
